Gln-NT Tablet is a combination pharmaceutical formulation containing Pregabalin 75 mg and Nortriptyline 10 mg, indicated for the management of neuropathic pain and certain mood disorders. Pregabalin, a structural analogue of gamma-aminobutyric acid (GABA), exerts its effect by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, thereby reducing the release of excitatory neurotransmitters and alleviating neuropathic pain symptoms. Nortriptyline, a tricyclic antidepressant, inhibits the reuptake of norepinephrine and serotonin, enhancing neurotransmitter availability and contributing to analgesic and mood-stabilizing effects. The synergistic action of these agents provides effective relief in conditions such as diabetic neuropathy, postherpetic neuralgia, and chronic neuropathic pain, while also addressing comorbid depressive symptoms. Gln-NT Tablet should be administered as prescribed by a healthcare professional, with dosage adjustments based on therapeutic response and tolerability. Caution is advised in patients with a history of cardiac arrhythmias, renal impairment, or hypersensitivity to either component. Common adverse effects may include dizziness, somnolence, dry mouth, and gastrointestinal disturbances. Regular monitoring and adherence to prescribed guidelines are essential to optimize therapeutic outcomes and minimize potential risks associated with this combination therapy.